PubMed Health⌕ Search

Biomedical subjects

J J Sands

Publications and source records attributed to J J Sands.

35 records · Page 2Linked to original sources
PubMed1988

The application of monoclonal antibody panels to characterize pestivirus isolates from ruminants in Great Britain.

Monoclonal antibodies were prepared against bovine virus diarrhoea virus and hog cholera virus. They were used to test 101 field isolates of ruminant pestivirus in a simple binding assay using an indirect immunoperoxidase label on fixed cell cultures. The monoclonals were divided into three panels: (1) pestivirus group specific, (2) hog cholera specific, (3) selectively reactive with ruminant pestiviruses. The reaction patterns with panel 3 were analyzed by a computer spreadsheet to determine the percentage match with seven reference patterns. Field viruses could be divided into two main groups. Group A consisted of 73 (87%) of the 84 bovine isolates and three (19%) of the 16 ovine, and was reactive with 40% or more of panel 3. Group B showed only limited reactivity with panel 3 and comprised 13/16 (81%) of the ovine (border disease) isolates together with the remaining 11 (13%) bovine viruses.

Animals↗
PubMed1984

Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1).

The suggestion that antibodies might enhance rabies virus infection of macrophages through opsonization of immune complexes was tested in vitro by adaptation of the rapid fluorescent focus inhibition technique for the examination of a macrophage cell line (P388D1). Some enhancement of rabies virus infection was shown. The relationship between such enhancement with the 'early death' phenomenon and its occurrence in vivo is discussed.

Animals↗
PubMed1982

Safety and efficacy of live and inactivated infectious bovine rhinotracheitis vaccines.

Two commercial live virus infectious bovine rhinotracheitis (IBR) vaccines for intranasal administration and an inactivated polyvalent calf pneumonia vaccine were compared for safety and efficacy in calves against experimental IBR infections. All three products were clinically safe for use in young calves; a mild, transient, febrile response was induced by one of the live vaccines. Vaccinal virus was recovered for up to 16 days after vaccination from nasal secretions of all calves given live vaccine. Both live vaccines stimulated a serum neutralising antibody response, but the inactivated vaccine failed to elicit any serological response. Following intranasal challenge four months after the first dose of vaccine, all live virus vaccinates remained systemically healthy. A slight nasal discharge and a few rapidly healing ulcers of the nasal mucosa were the only abnormalities observed. Both the group given the inactivated vaccine and the unvaccinated controls developed clinical IBR with pyrexia, ocular and nasal discharges, severe ulceration of the nasal mucosa and tracheitis and tachypnoea to varying degrees of severity. Parenteral administration of dexamethasone six months after challenge induced reactivation of virus shedding followed by a rise in humoral antibody titre irrespective of the original vaccination history.

Animals↗
PubMed1980

Bovine virus diarrhoea-mucosal disease virus: pathogenicity for the fetal calf following maternal infection.

Fifteen pregnant, bovine virus diarrhoea-mucosal disease (BVD-MD) antibody-free Jersey heifers were infected experimentally with a mixture of 10 cytopathic strains of BVD-MD virus isolated from cattle in Britain. Each cow was inoculated intramuscularly on gestation day 100 with a high or a low dose of virus grown in primary calf testis tissue cultures. None of the cows showed clinical signs of illness following exposure, but all had seroconverted within six weeks. Six fetuses, including one set of twins, died in utero following infection. Of these five were aborted between days 136 and 154; the sixth one was mummified and still retained at day 300. The remaining 10 fetuses survived to term, but all showed evidence of intrauterine growth retardation with or without gross malformation and/or dysmyelination of the central nervous system. Three were clinically affected with congenital nervous disease. Of the 10 liveborn fetuses, two had specific serum antibodies to BVD-MD. Non-cytopathic BVD-MD virus was recovered from all of the remaining eight. When non-immune cows become infected with BVD-MD virus in mid gestation: transplacental infection of the fetus will probably result; apart from the risk of fetal death, with or without abortion, there is a high probability of fetal mal-development which may not always be clinically obvious; the immunological competence of the fetus may be impaired; congenital infection is likely in a substantial proportion of liveborn calves. About one in 16 bovine fetuses in British herds are estimated to be at risk from BVD-MD virus infection.

Abortion, Veterinary↗
PubMed1978

Serological studies of mucosal disease virus in England and Wales.

A survey of the cattle population in England and Wales showed that about 62 per cent of animals had neutralising (SN) antibody to BVD-MD virus in their serum. Fewer seropositive individuals were detected by immunodiffusion (53 per cent), and complement fixation (CF) tests (34 per cent). The prevalence of antibody was not affected by herd size, but some variation was found between various regions of the country, and the proportion of animals seropositive rose markedly with age. The immunodiffusion test was a specific but relatively insensitive method of detecting antibody compared with the SN test. The data suggest that the CF test may detect a different, short-lived antibody. For diagnostic serology, the SN test was superior to the other methods. No antibody to the virus was detected in human or equine sera but about 7.3 per cent of sheep sampled had serum antibody to the virus in the immunodiffusion test.

Animals↗
PubMed1978

The distribution of antibodies to Border disease virus among sheep in England and Wales.

Within a sample of the sheep population of England and Wales, 10.8 per cent of 3506 individuals had immunodiffusion test antibody to bovine viral diarrhoea mucosal disease virus antigen. There were marked differences between various geographical regions in the proportion of sheep with antibody, and Border disease may be more common in some areas than disease records indicate.

Animals↗
PubMedDate not supplied

Increasing AV fistulas: revisiting a time-tested solution.

Despite having the lowest complication rate of all hemodialysis accesses, the prevalence of autologous arteriovenous (AV) fistulas has declined to 28% in the United States. The reasons for this decline include high early AV fistula failure rates, long maturation times, the frequent need for emergent dialysis, unavailable or poor pre-ESRD programs and planning, patient resistance to the realities of impending ESRD, and financial disincentives to AV fistula placement. Despite these barriers, programs throughout the country have demonstrated the ability to increase AV fistula prevalence to more than 50%. The strategies employed have included increased reliance on upper arm brachiocephalic and transposed basilic vein fistulas, the use of preoperative imaging to identify the best sites for fistula creation, and aggressive attempts at salvage of nonmaturing fistulas. Other groups have systematically and successfully replaced failed grafts with upper arm brachiocephalic or bracheobasilic fistulas. These experiences clearly show that exceeding the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) goal of more than 50% fistula placement is achievable in the United States. Declining numbers of AV fistulas are the result of a combination of factors, including changes in our patient population and learned practice patterns coupled with a failure of our delivery system to provide education, timely referral, and incentives for fistula placement. Increasing AV fistula prevalence in the United States is achievable and will improve patient outcomes and decrease the costs of ESRD.

Arteriovenous Shunt, Surgical↗
PubMedDate not supplied

Pharmacomechanical thrombolysis with urokinase for treatment of thrombosed hemodialysis access grafts. A comparison with surgical thrombectomy.

Seventy-one consecutively occluded polytetrafluoroethylene (PTFE) grafts treated with pharmacomechanical thrombolysis were compared with 75 surgical controls. The patients undergoing thrombomechanical lysis had a comparable rate of successful declotting (91% vs. 90.7%) and no significant difference in patency at 24 and 48 hr, 1 week, and 1 and 6 months. Patients undergoing thrombolysis required less overnight hospitalization (17 vs. 82%) (P < 0.001) and their hospital stays averaged 1.03 days versus 3.43 days in the surgical thrombectomy group (P < 0.0001). Complication rates were similar in both groups. Hospital charges and physician fees were significantly lower in the thrombolysis group, with total charges averaging $6,802 versus $12,740 (P = 0.0018). These cost differences were maintained even when patients with extended stays were excluded. In conclusion, pharmacomechanical thrombolysis provides efficacy and complications comparable to surgical thrombectomy, with the benefits of a decreased rate of hospitalization, decreased total number of days of hospitalization, and significant cost savings. The authors determined that pharmacomechanical thrombolysis is the preferable first intervention for acutely occluded PTFE grafts.

Blood Vessel Prosthesis↗
PubMedDate not supplied

Intervention based on monthly monitoring decreases hemodialysis access thrombosis.

We randomized 103 patients (68 arteriovenous [AV] fistulas, 35 polytetrafluoroethylene [PTFE] grafts; mean follow-up 197 days) to monthly measurement of access flow (QAT), monthly measurement of static venous pressure (VPS), or no monthly monitoring (control patients) to determine whether access thrombosis would decrease. Patients with access flow <750 cc/min or with static venous pressure > or =0.5 were referred for angiography and angioplasty of stenotic lesions > or =50%. Six of sixty-two (9.7%) of monthly monitored patients (MM) developed access thrombosis vs. 9 of 41 (22%) of control patients (p<0.05). Fewer MM patients developed thrombosis in AV fistulas (2.4% [2 of 42] vs. 15.4% [4 of 26] control patients; p<0.05). Monthly monitored patients had fewer thrombotic episodes than control patients (19 vs. 125 per 100 patient-years; p<0.01). Thrombosis rates were lowest in patients receiving monthly access flow measurement (5.9 [QAT] vs. 30.3 per 100 patient-years [VPS]; p<0.05). In conclusion, intervention based on monthly access flow measurement or static venous pressure decreased hemodialysis access thrombosis. Measurement of access flow tended to result in lower thrombosis rates than after static venous pressure. We believe that monthly access flow measurement will ensure the lowest incidence of thrombosis and decrease the cost of access maintenance.

Arteriovenous Anastomosis↗
PubMedDate not supplied

Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis.

We studied 88 hemodialysis patients for the presence of antibodies to human factor II (hFII), bovine factor V (bFV), and human beta2-glycoprotein 1 (beta2GPI). Forty-one patients had elevated anti-hFII antibodies, 17 had elevated anti-bFV antibodies, and 9 had elevated anti-beta2GPI antibodies. Fifty-two patients had elevated antibodies to one or more protein. Patients with PTFE grafts had elevated antibodies most frequently (21 [75%] vs. 20 fistulas [45%; p = 0.016 compared with PTFE] and 11 tunneled catheters [68.8%]). Twelve of 13 patients (92.3%) with PTFE grafts and thrombosis had elevated antibody levels, compared with 9 of 15 without thrombosis (60%; p = 0.049). The number of thromboses and mean thrombosis rates were significantly higher in PTFE patients with antibodies (1.24 vs. 0.14 thromboses, p < 0.01; 42.67 vs. 6.44 thromboses/100 patient years, p < 0.05). When analyzed individually, thrombotic complications occurred more frequently in patients with PTFE grafts and elevated anti-bFV antibodies (p = 0.016), but did not correlate with anti-hFII or anti-beta2GPI antibodies. Thrombotic complications did not correlate with elevated antibody levels in patients with AV fistulas or cuffed catheters. In conclusion, hemodialysis patients with PTFE grafts frequently have elevated antibodies to FII, FV, and beta2GPI, and the presence of elevated antibody levels to one or more of these proteins is associated with an increased thrombotic risk. Further studies are necessary to determine whether limiting exposure to bovine thrombin preparations will decrease the incidence of these antibodies and PTFE graft thrombosis.

Aged↗